Previous 10 |
Vallon Pharmaceuticals (VLON) provides a clinical program update for its lead program, ADAIR, a abuse-deterrent formulation of immediate-release ((IR)) dextroamphetamine currently in development for the treatment of attention deficit hyperactivity disorder ((ADHD)) and narcolepsy. “Our...
- Ongoing ADAIR SEAL study on target for pivotal data readout in second half of 2021 - Target NDA filing in Q2 2022 for a potential abuse-deterrent alternative to commercially available IR amphetamines in the treatment of ADHD, a ~$9 billion U.S. market 1 PHILADELPHIA, P...
SOS (SOS) +36%.Titan Medical (TMDI) +25%.CBAK Energy Technology (CBAT) +21%.Altimeter Growth (AGCUU) +18%.CA Healthcare Acquisition (CAHCU) +16%.TransMedics (TMDX) +16%. as FDA Advisory Panel has issued a favorable vote in support of approval of the OCS Heart System.Altimeter Growth (AGC...
Vallon Pharmaceuticals (VLON): FY net loss of ~$4.8MCash and cash equivalents of ~$109KPress Release For further details see: Vallon Pharmaceuticals reports FY results
- Pivotal data from lead program, ADAIR, expected in second half 2021 - Potential NDA filing for ADAIR in Q2 2022; targeting a ~$9 billion U.S. ADHD market 1 - Novel abuse-deterrent platform technology enables pipeline expansion opportunities across multiple drugs an...
The following slide deck was published by Vallon Pharmaceuticals, Inc. in conjunction with this event. For further details see: Vallon Pharmaceuticals (VLON) Investor Presentation - Slideshow
News, Short Squeeze, Breakout and More Instantly...
Vallon Pharmaceuticals Inc. Company Name:
VLON Stock Symbol:
NASDAQ Market:
Combined company will operate as GRI Bio , Inc. and advance i nnovative p ipeline of Natural Killer T ( “ NKT ” ) modulating therapies for the treatment of i nflammatory, f ibrotic and a utoimmune d ...
Vallon’s b oard approves 1-for-30 r everse stock split Merger expected to close April 21, 2023 PHILADELPHIA, PA, April 20, 2023 (GLOBE NEWSWIRE) -- Vallon Pharmaceuticals, Inc. (NASDAQ: VLON) (“Vallon” or the “Company”) toda...
Board of Directors unanimously recommend Vallon stockholders to vote “ FOR ” all proposals outlined in the Company’s definitive Proxy Statement (the “Proxy”) in order to close the proposed merger with GRI Bio , Inc. ...